AACE 2026: Empagliflozin Shows Lower PE and DVT Risk vs Dapagliflozin Tags SGLT-2 Inhibitor Read more about AACE 2026: Empagliflozin Shows Lower PE and DVT Risk vs Dapagliflozin
Higher HbA1c Threshold May Better Stratify Adult T1DM Risk Tags hBA1c Read more about Higher HbA1c Threshold May Better Stratify Adult T1DM Risk
AACE 2026: Basal-Based Insulin Improves Inpatient Glycemic Control in T2DM Tags Hyperglycemia hyperosmolar state Long acting Read more about AACE 2026: Basal-Based Insulin Improves Inpatient Glycemic Control in T2DM
AACE 26: Synthetic Semaglutide Delivers Similar HbA1c, Weight Outcomes in T2DM Tags GLP-1 agonists PLBS hBA1c Read more about AACE 26: Synthetic Semaglutide Delivers Similar HbA1c, Weight Outcomes in T2DM
Brolucizumab Improves BCVA Compared With PRP in PDR Tags Retinopathy Read more about Brolucizumab Improves BCVA Compared With PRP in PDR
T Cell Immunotherapy Preserves β-Cell Function in New-Onset T1DM Read more about T Cell Immunotherapy Preserves β-Cell Function in New-Onset T1DM
Early AID Adoption in New-Onset T1DM Shows Low Hypoglycemia Burden Tags Diabetic ketoacidosis Hypoglycemia Insulin Pumps Others Delivery devices Continuous glucose monitoring (CGM) Read more about Early AID Adoption in New-Onset T1DM Shows Low Hypoglycemia Burden
AACE 2026: LSM Declines Across Fibrosis Stages With Empagliflozin Tags SGLT-2 Inhibitor Read more about AACE 2026: LSM Declines Across Fibrosis Stages With Empagliflozin
AACE 2026: Inpatient Glycemia Improves With Insulin Pump Continuation Tags Hypoglycemia Insulin Pumps Read more about AACE 2026: Inpatient Glycemia Improves With Insulin Pump Continuation
Prolonged Glucose Excursions Drive GMI-HbA1c Discordance in T1DM Tags hBA1c Continuous glucose monitoring (CGM) Read more about Prolonged Glucose Excursions Drive GMI-HbA1c Discordance in T1DM